Published in Proc Soc Exp Biol Med on October 01, 1963
Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J Virol (1988) 2.61
Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol (1996) 2.46
Mechanism by which fiber antigen inhibits multiplication of type 5 adenovirus. J Virol (1967) 2.44
PRODUCTION OF TYPE-SPECIFIC C ANTIGEN IN VIRUS-FREE HAMSTER TUMOR CELLS INDUCED BY ADENOVIRUS TYPE 12. Proc Natl Acad Sci U S A (1964) 2.13
Evidence that the penton base of adenovirus is involved in potentiation of toxicity of Pseudomonas exotoxin conjugated to epidermal growth factor. Mol Cell Biol (1984) 1.76
Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J Virol (1998) 1.55
Characterization of two temperature-sensitive mutants of type 5 adenovirus with mutations in the 100,000-dalton protein gene. J Virol (1981) 1.26
Immunological and other biological characteristics of pentons of human adenoviruses. J Virol (1969) 1.26
Immunological basis of the adenovirus 8-9 cross-reaction. J Virol (1970) 1.19
Interaction between HeLa cells and adenovirus type 2 virions neutralized by different antisera. J Virol (1985) 1.12
Purification and preliminary immunological characterization of the type 5 adenovirus, nonstructural 100,000-dalton protein. J Virol (1980) 1.08
Immunological relationships between hexons of certain human adenoviruses. J Virol (1969) 1.04
A Soluble Precipitating Antigen From Hog Cholera Virus Propagated in Tissue Culture: I. Preparation and Characterization of the Antigen. Can J Comp Med Vet Sci (1964) 1.03
Hexon peptides of type 2, 3, and 5 adenoviruses and their relationship to hexon structure. J Virol (1975) 0.99
Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway. J Virol (2006) 0.92
Liposomal enhancement of the immunogenicity of adenovirus type 5 hexon and fiber vaccines. Infect Immun (1979) 0.91
Characterization of group II avian adenoviruses with a panel of monoclonal antibodies. Can J Vet Res (1988) 0.77
Nature of hamster complement-fixing antibody to adenovirus 12 tumor antigen. J Virol (1967) 0.75
Potency of adenovirus vaccines: comparison of unconcentrated, concentrated, and soluble antigen preparations. Appl Microbiol (1966) 0.75
Soluble components of adenovirus type 8. J Virol (1970) 0.75
Purification and immunological characterization of types 4 and 5 adenovirus-soluble antigens. Proc Natl Acad Sci U S A (1961) 3.65
The inhibitory effect of polysaccharide on mumps virus multiplication. J Exp Med (1948) 3.56
Etiologic relationship of the RI-67 agent to acute respiratory disease (ARD). J Clin Invest (1955) 2.90
Sequential cellular changes produced by types 5 and 7 adenoviruses in HeLa cells and in human amniotic cells; cytological studies aided by fluorescein-labelled antibody. J Exp Med (1959) 2.73
Tryptose phosphate broth as supplementary factor for maintenance of HeLa cell tissue cultures. Proc Soc Exp Biol Med (1955) 2.69
Cytological and cytochemical studies of HeLa cells infected with adeno-viruses. J Exp Med (1957) 2.44
Synthesis of virus-specific polymers in adenovirus-infected cells; effect of 5-fluorodeoxyuridine. J Exp Med (1962) 2.44
Quantitative aspects of the multiplication of influenza A virus in the mouse lung; relation between the degree of viral multiplication and the extent of pneumonia. J Exp Med (1952) 2.36
The reaction of influenza viruses with guinea pig polymorphonuclear leucocytes. II. The reduction of white blood cell glycolysis by influenza viruses and receptor-destroying enzyme (RDE). Virology (1956) 2.17
A SHORT DESCRIPTION OF THE ADENOVIRUS GROUP. Virology (1963) 2.09
A labile component of normal serum which combines with various viruses; neutralization of infectivity and inhibition of hemagglutination by the component. J Exp Med (1949) 1.98
Immunohistochemical studies on the interaction between Ehrlich ascites tumor cells and Newcastle disease virus. J Exp Med (1957) 1.85
STRUCTURE OF TYPE 5 ADENOVIRUS. II. FINE STRUCTURE OF VIRUS SUBUNITIS. MORPHOLOGIC RELATIONSHIP OF STRUCTURAL SUBUNITS TO VIRUS-SPECIFIC SOLUBLE ANTIGENS FROM INFECTED CELLS. J Exp Med (1963) 1.83
Characteristics on the adenoviruses. III. Reproductive cycle of types 1 to 4. J Exp Med (1958) 1.79
A toxin-like material separable from type 5 adenovirus particles. Virology (1958) 1.79
Characteristics of the multiplication cycle of pneumonia virus of mice (PVM). J Exp Med (1951) 1.77
The dependence of the pathological lesion upon the multiplication of pneumonia virus of mice (PVM); kinetic relation between the degree of viral multiplication and the extent of pneumonia. J Exp Med (1951) 1.77
An improved CO2 cabinet for low temperature storage of infectious agents with gaseous CO2 excluded from the specimen compartment. J Bacteriol (1951) 1.76
Nucleuc acid synthesis in types 4 and 5 adenovirus-infected HeLa cells. J Exp Med (1961) 1.75
A resistant variant of mumps virus; multiplication of the variant in the presence of inhibitory quantities of Friedländer bacillus polysaccharide. J Exp Med (1949) 1.74
Therapy of infection with pneumonia virus of mice (PVM); effect of a polysaccharide on the multiplication cycles of the virus and on the course of the viral pneumonia. J Exp Med (1951) 1.72
STRUCTURE OF TYPE 5 ADENOVIRUS. I. ANTIGENIC RELATIONSHIP OF VIRUS-STRUCTURAL PROTEINS TO VIRUS-SPECIFIC SOLUBLE ANTIGENS FROM INFECTED CELLS. J Exp Med (1963) 1.69
Identification and classification of adenoviruses. Virology (1962) 1.63
Mechanism of production of pulmonary lesions in mice by Newcastle disease virus (NDV). J Exp Med (1951) 1.59
Relation of the new respiratory agents to acute respiratory diseases. Am J Public Health Nations Health (1955) 1.58
Deoxyribonucleic acid (DNA) and protein alterations in HeLa cells infected with type 4 adenovirus. J Exp Med (1959) 1.57
Evidence for the specific etiology of acute respiratory disease (ARD). Trans Assoc Am Physicians (1954) 1.57
The effect of polysaccharides on the reaction between erythrocytes and viruses, with particular reference to mumps virus. J Exp Med (1948) 1.56
The significance of the viral carrier state in tissue culture systems. Prog Med Virol (1958) 1.54
Protein synthesis in type 5 adenovirus-infected cells. Effect of p-flourophenylalanine on synthesis of protein. nucleic acids, and infectious virus. Virology (1963) 1.50
Characteristics of the new respiratory viruses (adenoviruses). I. Qualitative and quantitative aspects of the neutralization reaction. J Immunol (1956) 1.48
Morphological and functional changes in corneal endothelium caused by the toxic effects of influenza and Newcastle disease viruses. Br J Exp Pathol (1958) 1.41
A study of illness in a group of Cleveland families. X. The occurrence of adenovirus infections. Am J Hyg (1956) 1.32
Biological and biochemical basis for cell injury by animal viruses. Fed Proc (1961) 1.30
Suppression of influenza viral pneumonia in mice by the non-specific action of xerosin. J Immunol (1955) 1.27
Concurrent infection with influenza virus and mumps virus or pneumonia virus of mice as bearing on the inhibition of virus multiplication by bacterial polysaccharides. J Exp Med (1949) 1.27
Reactions of influenza viruses with guinea pig polymorphonuclear leucocytes. I. Virus-cell interactions. Virology (1956) 1.26
Characteristics of the new respiratory viruses (adenoviruses). II. Stability to temperature and pH alterations. Proc Soc Exp Biol Med (1956) 1.24
The properdin system and immunity. VI. The inactivation of Newcastle disease virus by the properdin system. J Exp Med (1956) 1.16
Pulmonary embolism. Roentgenographic and angiographic considerations. Am J Roentgenol Radium Ther Nucl Med (1963) 1.15
The reaction of influenza viruses with guinea pig polymorphonuclear leucocytes. III. Studies on the mechanism by which influenza viruses inhibit phagocytosis. Virology (1956) 1.14
Intracellular localization of type 4 adenovirus. II. Cytological and fluorescein-labelled antibody studies. J Exp Med (1959) 1.14
Inactivation of several viruses by liquid ethylene oxide. Proc Soc Exp Biol Med (1950) 1.03
Certain biological characteristics of adenovirus types 5, 6, 7 and 14. J Immunol (1961) 0.95
Newer aspects of adenovirus infections. Am J Public Health Nations Health (1959) 0.94
Formation of non-infectious influenza virus in mouse lungs: its dependence upon extensive pulmonary consolidation initiated by the viral inoculum. J Exp Med (1954) 0.93
Biological and physical properties of the adenoviruses. Ann N Y Acad Sci (1957) 0.92
Production of pulmonary lesions by influenza viruses in immunized mice. J Immunol (1954) 0.91
Acute hemolytic anemia in primary atypical pneumonia associated with high titer of cold agglutinins; report of a case. N Engl J Med (1946) 0.90
Properdin and the inactivation of viruses. Ann N Y Acad Sci (1960) 0.90
Comparison of quantity of egg and mouse-adapted influenza viruses required to infect each host. Proc Soc Exp Biol Med (1953) 0.89
Methods for quantitative bioassay of Ehrlich ascites-tumors cells. J Natl Cancer Inst (1957) 0.86
Hemagglutination with adenoviruses; nature of viral antigen. Proc Soc Exp Biol Med (1958) 0.83
Studies on the mechanism of polysaccharide inhibition of virus multiplication. Bull N Y Acad Med (1948) 0.83
Effect of proflavine on the synthesis of adenovirus, type 5, and associated soluble antigens. J Bacteriol (1962) 0.82
Studies on the cytotoxic effect of Newcastle disease virus (NDV) on Ehrlich ascites tumor cells. I. Characteristics of the virus-cell interaction. J Immunol (1957) 0.81
Accumulation of organic acids by HeLa cells infected with type 4 adenovirus. Proc Soc Exp Biol Med (1957) 0.81
Serum and tissue inhibitors of virus. Bacteriol Rev (1960) 0.81
Interference between mumps virus and pneumonia virus of mice (PVM) fate of mumps virus in the mouse lung. J Immunol (1951) 0.81
Intracellular localization of type 4 adenovirus. I. Cellular fractionation studies. J Exp Med (1959) 0.80
An inhibitor of adenoviruses in ox serum. J Immunol (1962) 0.80
Studies on the cytotoxic effect of Newcastle disease virus (NDV) on Ehrlich ascites tumor cells. II. The mechanism and significance of in vitro recovery from the effect of NDV. J Immunol (1957) 0.77
Epidemiological studies of psittacosis in Cleveland. Am J Hyg (1956) 0.77
Studies on the mechanism of the toxic action of Newcastle disease virus. Bull N Y Acad Med (1951) 0.75
Antigenic similarity between the first and later egg passage strains of freshly recovered influenza A viruses. Proc Soc Exp Biol Med (1952) 0.75
New respiratory viruses. Am Pract Dig Treat (1962) 0.75
Cellular immunity of monkeys versus antibody titers following oral inoculation with poliomyelitis virus. J Immunol (1955) 0.75
Modification of viral multiplication in the chick embryo. Ann N Y Acad Sci (1952) 0.75
[Virus diseases of the respiratory tract]. Klin Wochenschr (1957) 0.75
Modification of the course of a viral pneumonia in mice. Bull N Y Acad Med (1950) 0.75
In vitro reactions of pneumonia virus of mice (PVM). Fed Proc (1951) 0.75
Inhibition of mumps virus multiplication by a polysaccharide. Proc Soc Exp Biol Med (1947) 0.75
The implications of chemical interruption of viral multiplication. Trans Assoc Am Physicians (1950) 0.75
An antipyretic action of aureomycin; inhibition of febrile response to influenza virus in rabbits. Proc Soc Exp Biol Med (1954) 0.75
Serological studies on a family epidemic of primary atypical pneumonia. Acta Med Scand (1948) 0.75
ANGIOGRAPHY OF THE SYSTEMIC PULMONARY CIRCULATION. Am J Roentgenol Radium Ther Nucl Med (1963) 0.75
Homologous serum jaundice following plasma. Med Bull U S Army Force Europe Theater Off Theater Chief Surg (1945) 0.75
Acute thrombocytopenic purpura complicating rubella. Am J Med (1947) 0.75
Relationship of certain characteristics of the new respiratory viruses to the clinical and epidemiological behavior of non-bacterial pharyngitis. Trans Assoc Am Physicians (1955) 0.75
Relationship of physiological inhibitor of hyaluronidase to experimental poliomyelitis. Proc Soc Exp Biol Med (1955) 0.75
Homologous serum hepatitis following transfusion. Arch Intern Med (Chic) (1947) 0.75
The effect of polysaccharides on virus activity. J Clin Invest (1948) 0.75